Chronic prostatitis and small intestinal bacterial overgrowth: Effect of rifaximin

Canadian Journal of Urology

Volumn 18, Issue 4, 2011, Pages 5826-5830

  Weinstock, Leonard B ^a,b   Geng, Bob ^a   Brandes, Steven B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Specialists in Gastroenterology LLC   (United States)

Author keywords

Antibiotic; Chronic prostatitis; CPSI score; Lactulose breath test; Rifaximin; Small intestinal bacterial overgrowth

Indexed keywords

ANTIINFECTIVE AGENT; RIFAMYCIN; RIFAXIMIN;

ADULT; ARTICLE; BLIND LOOP SYNDROME; BREATH ANALYSIS; CHRONIC DISEASE; CLINICAL TRIAL; HUMAN; IRRITABLE COLON; MALE; MASS SCREENING; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; PILOT STUDY; PREVALENCE; PROSTATITIS; SMALL INTESTINE; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; BLIND LOOP SYNDROME; BREATH TESTS; CHRONIC DISEASE; HUMANS; INTESTINE, SMALL; IRRITABLE BOWEL SYNDROME; MALE; MASS SCREENING; MIDDLE AGED; PILOT PROJECTS; PREVALENCE; PROSTATITIS; RIFAMYCINS; TREATMENT OUTCOME;

EID: 84856017074     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Murphy AB, Macejko A, Taylor A et al. Chronic prostatitis: management strategies. Drugs 2009;69(1):71-84.
2. Schaeffer AJ. Etiology and management of chronic pelvic pain syndrome in men. Urology 2004;63(Suppl 1):75-84.
3. Alexander RB, Ponniah S, Hasday J et al. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology 1998;52(5):744-749.
4. Orhan I, Onur R, Ilhan N et al. Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome. Int J Urol 2001;8(9):495-499.
5. John H, Barghorn A, Funke G et al. Noninflammatory chronic pelvic pain syndrome: immunological study in blood, ejaculate and prostate tissue. Eur Urol 2001;39(1):72-78.
6. Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 2004;172(3):839-845.
7. Dimitrakov JD, Kaplan SA, Kroenke K et al. Management of chronic prostatitis/chronic pelvic pain syndrome: an evidencebased approach. Urology 2006;67(5):881-888.
8. Nickel JC, Downey J, Pontari MA et al. A randomized placebocontrolled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int 2004;93(7):991-995.
9. Bates SM, Hill VA, Anderson JB et al. A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/ chronic pelvic pain syndrome. BJU Int 2007;99(2):355-359.
10. Weinstock LB, Klutke CG, Lin HC. Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms. Dig Dis Sci 2008;53(5):1246-1251.
11. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007;52:139-142.
12. Pimentel M, Park S, Mirocha J et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med 2006;145(8):557-563.
13. Gregg CR, Toskes PP. Enteric bacterial flora and small bowel bacterial overgrowth syndrome. In: Feldman M, Friedman LS, Sleisenger MH, editors. Gastrointestinal and Liver Disease. 7th ed. Philadelphia: Saunders; 2002:1783-1793.
14. Parodi A, Dulbecco P, Savarino E et al. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. J Clin Gastroenterol 2009;43(10):962-966.
15. Peralta S, Cottone C, Doveri T et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with rifaximin. World J Gastroenterol 2009;15(21):2628-2631.
16. Pimentel M, Lembo A, Chey WD et al; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364(1):22-32.
17. Litwin MS, McNaughton-Collins M, Fowler FJJ et al; Chronic Prostatitis Collaborative Research Network. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol 1999;162(2):369-375.
18. Weinstock LB, Fern SE, Duntley SP. Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy. Dig Dis Sci 2008;53(5):1252-1256.
19. Weinstock L, Walters A. Small intestinal bacterial overgrowth (SIBO) in restless legs syndrome (RLS): insight into the etiology of central nervous system (CNS) iron deficiency. Gastroenterology 2010;138(Suppl 1):S-751.
20. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45(Suppl 2):43-47.
21. Andrews EB, Eaton SC, Hollis KA et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005;22(10):935-942.
22. Cox CE, Childs SJ. Treatment of chronic bacterial prostatitis with temafloxacin. Am J Med 1991;91(6A):134S-139S.
23. Skerk V, Schönwald S, Krhen I et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents 2003;21(5):457-462.
24. Landry C, Vidon N, Sogni P et al. Effects of erythromycin on gastric emptying, duodeno-caecal transit time, gastric and biliopancreatic secretion during continuous gastric infusion of a liquid diet in healthy volunteers. Eur J Gastroenterol Hepatol 1995;7(8):797-802.
25. Lupascu A, Lauritano C, Gabrielli M et al. Antibiotic treatment in small bowel bacterial overgrowth in patients with irritable bowel. Gastroenterology 2005;128(Suppl 2):A-674.
26. Khoshini R, Dai SC, Lezcano S et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008;53(6):1443-1454.
27. Weinstock LB, Todorczuk JR, Fern SE et al. Comprehensive small intestinal bacterial overgrowth (SIBO) therapy for irritable bowel syndrome (IBS). Am J Gastroenterol 2006;101(Suppl 2):S470-S471.